Baird Maintains Outperform on Regenxbio, Lowers Price Target to $29
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Baird analyst Brian Skorney maintains Regenxbio (NASDAQ:RGNX) with a Outperform and lowers the price target from $32 to $29.
Baird analyst Brian Skorney maintains Regenxbio (NASDAQ:RGNX) with a Outperform and lowers the price target from $32 to $29.